Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon. But a new study suggests that it might take a while for us to get there. The ...
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense ...
Anthropic executives Eric Kauderer-Abrams and Jonathan “JP” Pelosi explain how Claude is moving beyond AI assistants into ...
The legendary Google executive is joined by other outgoing Google execs in a joint mission to use AI to push forward the process of scientific discovery.
The study says AI use is spreading across the drug-development process and tracks strategies among pharma groups, AI ventures ...
Anthropic's latest research showcases automated systems enhancing AI alignment benchmarks, achieving consistent improvements ...
Gemini 4 and OpenAI Astra test internal boundaries while Ilya Sutskever's speculated SSI model secures NVIDIA funding to ...
Opinion
8dOpinion
Would even an AI disaster on the scale of Hiroshima be enough to make humankind protect itself? I fear not
It’s clear here in Silicon Valley that AI is advancing faster than humans’ ability to control it. That means even sober prophecies seem optimistic, says Guardian columnist Timothy Garton Ash ...
AI is approaching the limits of human-generated training data. Explore model collapse, synthetic data, and why preserving ...
The tech industry is realizing it needs to build agents based on what regular consumers want, not just what its AI models can do.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results